Free Trial
NASDAQ:CGEM

Cullinan Therapeutics Q4 2024 Earnings Results & Report

Cullinan Therapeutics logo
$10.28 +0.09 (+0.88%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$10.27 -0.01 (-0.10%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cullinan Therapeutics beat analyst earnings expectations in its Q4 2024 results, released February 27, 2025. The company reported EPS of -$0.73 versus the -$0.75 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call
7:00 AM ET

Cullinan Therapeutics EPS Results

Actual EPS
-$0.73
Consensus EPS
-$0.75
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Cullinan Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cullinan Therapeutics Q4 2024 Earnings FAQ

Cullinan Therapeutics (NASDAQ:CGEM) reported earnings of -$0.73 per share for Q4 2024, beating the consensus estimate of -$0.75. The report was announced on Thursday, February 27, 2025.

Cullinan Therapeutics Earnings Headlines

Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $44.00
BTIG Reaffirms Their Buy Rating on Cullinan Management (CGEM)
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
See More Cullinan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cullinan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cullinan Therapeutics and other key companies, straight to your email.

About Cullinan Therapeutics

Cullinan Therapeutics (NASDAQ:CGEM) is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells.

Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases. These candidates remain investigational and are not approved treatments.

Founded as Cullinan Oncology, the company adopted the name Cullinan Therapeutics in 2024 to reflect its expanded focus beyond oncology. It is headquartered in Cambridge, Massachusetts, and is led by President and Chief Executive Officer Nadim Ahmed.

View Cullinan Therapeutics Profile